ArticleBMC public health2025
Cost-effectiveness analysis of different types of human papillomavirus vaccination to prevent cervical cancer in Iran.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) remains a major public health concern, especially in low- and middle-income countries (LMICs), where prevention and screening access are limited. Iran has a relatively low incidence of CC (age-standardized incidence rate: 2.2 per 100,000 women), but a high mortality-to-incidence ratio (44%), which suggests diagnoses occur at later stages. Despite the availability of three prophylactic HPV vaccines (bivalent, quadrivalent, and nine-valent), their cost-effectiveness in Iran is still uncertain. This study evaluates the economic and health impacts of HPV vaccination strategies in Iran.
methodsA static Markov cohort model simulated the lifetime effects of HPV vaccination on a hypothetical cohort of 100,000 twelve-year-old girls. The model incorporated Iranian epidemiological data, vaccine efficacy, and direct medical costs (vaccination, screening, and treatment). Outcomes included cases of cervical intraepithelial neoplasia (CIN), CC, genital warts (G W), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses assessed robustness.
resultsThe nine-valent vaccine demonstrated the highest effectiveness, reducing CC cases by 98.4% and deaths by 99%. It was followed by the bivalent vaccine, which resulted in a 95.7% reduction in CC, and the quadrivalent vaccine, which achieved a 90.4% reduction. However, none of these vaccines is cost-effective at current prices. The ICERs are significantly above Iran’s cost-effectiveness threshold of $4,761.90 per QALY (1 times the gross domestic product (GDP) per capita). Specifically, the bivalent vaccine has an ICER of $33,179/QALY, the quadrivalent $45,088/QALY, and the nine-valent $50,067/QALY. Threshold analysis showed that vaccine prices would need to decrease by 82–85% to be considered cost-effective. Probabilistic sensitivity analysis confirmed that vaccination strategies remained not cost-effective across parameter uncertainties.
conclusionsAlthough HPV vaccines provide health benefits, they are not cost-effective in Iran at current prices due to high costs and low CC rates. Substantial price reductions are needed to support nationwide HPV vaccination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.